Gastric Cancer Risk and Pathogenesis in and Carriers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Dec 11

PMID 36497436

Authors

Kole H Buckley

Blake A Niccum

Kara N Maxwell

Bryson W Katona

Affiliations

Soon will be listed here.

Abstract

Carriers of a pathogenic germline variant (PV) in or are at increased risk for a number of malignancies, including breast, ovarian, pancreatic, and prostate cancer. In this review, we discuss emerging evidence that PV carriers, and likely also PV carriers, are also at increased risk for gastric cancer (GC), highlighting that GC may be part of the cancer risk spectrum. While the pathogenesis of GC among PV carriers remains unclear, increasing evidence reveals that GCs are often enriched with mutations in homologous recombination-associated genes such as , and that GC prognosis and response to certain therapies can depend on BRCA1/2 expression. Given the strength of data published to date, a risk management strategy for GC among PV carriers is needed, and herein we also propose a potential strategy for GC risk management in this population. Moving forward, further study is clearly warranted to define the mechanistic relationship between PVs and development of GC as well as to determine how GC risk management should be factored into the clinical care of carriers.

Citing Articles

Diagnostics and Therapy for Malignant Tumors.

Tsai C, Wang C, Chang H, Chang P, Chang C, Chu T Biomedicines. 2025; 12(12.

PMID: 39767566 PMC: 11726849. DOI: 10.3390/biomedicines12122659.

The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation.

Katona B, Lubinski J, Pal T, Huzarski T, Foulkes W, Moller P Cancer. 2024; 131(1):e35666.

PMID: 39611336 PMC: 11694537. DOI: 10.1002/cncr.35666.

Exploration of BRCA1 and BRCA2 mutations in gastric cancer patients through next generation sequencing: implications for diagnosis and therapy.

Ahmed I, Anwar S, Akram M, Zeb U, Bharadwaj A, Zia R Am J Transl Res. 2024; 16(10):5357-5370.

PMID: 39544817 PMC: 11558441. DOI: 10.62347/KJYY7691.

Unraveling the regulatory cell death pathways in gastric cancer: a multi-omics study.

Sun J, Rao L, Zhou S, Zeng Y, Sun Y Front Pharmacol. 2024; 15:1447970.

PMID: 39314752 PMC: 11417042. DOI: 10.3389/fphar.2024.1447970.

Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

Ramaswamy A, Bhargava P, Dubashi B, Gupta A, Kapoor A, Srinivas S JNCI Cancer Spectr. 2024; 8(4).

PMID: 39067037 PMC: 11316615. DOI: 10.1093/jncics/pkae054.

References

Ichikawa H, Wakai T, Nagahashi M, Shimada Y, Hanyu T, Kano Y . Pathogenic germline mutations and familial predisposition to gastric cancer. JCO Precis Oncol. 2019; 2. PMC: 6788804. DOI: 10.1200/PO.18.00097. View

Ansari S, Gantuya B, Tuan V, Yamaoka Y . Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity. Int J Mol Sci. 2018; 19(8). PMC: 6121269. DOI: 10.3390/ijms19082424. View

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J . Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378(6559):789-92. DOI: 10.1038/378789a0. View

Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I . Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Ann Oncol. 2020; 31(11):1545-1552. DOI: 10.1016/j.annonc.2020.06.025. View

Mersch J, Jackson M, Park M, Nebgen D, Peterson S, Singletary C . Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2014; 121(2):269-75. PMC: 4293332. DOI: 10.1002/cncr.29041. View

Zhang Z, Liu Y, Yin X, Zhan P, Gu Y, Ni X . Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. World J Gastroenterol. 2013; 19(12):1968-74. PMC: 3613113. DOI: 10.3748/wjg.v19.i12.1968. View

Ranjha L, Howard S, Cejka P . Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. Chromosoma. 2018; 127(2):187-214. DOI: 10.1007/s00412-017-0658-1. View

Jakubowska A, Nej K, Huzarski T, Scott R, Lubinski J . BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer. 2002; 87(8):888-91. PMC: 2376177. DOI: 10.1038/sj.bjc.6600562. View

Aslanian H, Lee J, Canto M . AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020; 159(1):358-362. DOI: 10.1053/j.gastro.2020.03.088. View

10.

Polk D, Peek Jr R . Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10(6):403-14. PMC: 2957472. DOI: 10.1038/nrc2857. View

11.

Boland C, Idos G, Durno C, Giardiello F, Anderson J, Burke C . Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2022; 117(6):846-864. DOI: 10.14309/ajg.0000000000001755. View

12.

Lu C, Xie M, Wendl M, Wang J, McLellan M, Leiserson M . Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015; 6:10086. PMC: 4703835. DOI: 10.1038/ncomms10086. View

13.

Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D . Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014; 66(3):489-99. PMC: 4105321. DOI: 10.1016/j.eururo.2014.01.003. View

14.

Ford D, Easton D, Bishop D, Narod S, Goldgar D . Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343(8899):692-5. DOI: 10.1016/s0140-6736(94)91578-4. View

15.

Powell S, Kachnic L . Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003; 22(37):5784-91. DOI: 10.1038/sj.onc.1206678. View

16.

Walsh C . Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015; 137(2):343-50. DOI: 10.1016/j.ygyno.2015.02.017. View

17.

Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A . The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer. 2001; 84(4):478-81. PMC: 2363777. DOI: 10.1054/bjoc.2000.1605. View

18.

Tulinius H, Olafsdottir G, Sigvaldason H, Arason A, Barkardottir R, Egilsson V . The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet. 2002; 39(7):457-62. PMC: 1735175. DOI: 10.1136/jmg.39.7.457. View

19.

Maxwell K, Wubbenhorst B, Wenz B, De Sloover D, Pluta J, Emery L . BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017; 8(1):319. PMC: 5567274. DOI: 10.1038/s41467-017-00388-9. View

20.

Tavakoli A, Monavari S, Solaymani Mohammadi F, Kiani S, Armat S, Farahmand M . Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2020; 20(1):493. PMC: 7268387. DOI: 10.1186/s12885-020-07013-x. View